Andrew Murray

Kopin Corporation ( NASDAQ:KOPN Get Free Report ) CEO Michael Andrew Murray sold 63,200 shares of the company's stock in a transaction dated Wednesday, April 15th.

LOCATION Pirates Tavern 82, Rear of, Nelson Pl, Williamstown VIC 3016 DATE Sun 17 May 2026 Time 1pm

LOCATION The Catfish 30 Gertrude St, Fitzroy VIC 3065 DATE Sun 03 May 2026 Time 4pm PRICE

Sleep deprivation affects the very capacities that good teaching depends on.

This is a full stop to a nothing

AS THOUSANDS of artificial intelligence builders, investors and policymakers gathered in Singapore on Wednesday (Jun 10) for SuperAI – a two-day

LOCATION Republic Shiraz, 507 Hamblin Rd, Cornella VIC 3551 DATE Sun 28 Jun 2026 Time 2pm PRICE

Objective To map current strategies for weight loss in hip and knee osteoarthritis (OA), with emphasis on the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) as tools in achieving weight loss and impacting symptoms, disease progression and perioperative outcomes in individuals with obesity.Design Scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and methodological guidance from the Joanna Briggs Institute and Arksey and O’Malley.Data sources PubMed, Web of Science, Directory of Open Access Journals, Scopus, ProQuest Central (1 January 2010 to 18 August 2025).Eligibility criteria Included studies focused on adults (≥18 years) with obesity and hip or knee OA, examined weight-loss strategies (nutritional, physical activity, surgical or pharmacological) including GLP-1-RAs.Results Of 199 included studies, 36 (18.1%) directly assessed GLP-1-RAs and of these, 14/36 (38.9%) reported original data. Evidence was heavily skewed towards knee OA, with limited hip-specific data. Descriptive analysis revealed a narrow geographical distribution of studies and a rapidly increasing focus on GLP-1-RAs; most studies involving GLP-1-RAs (29/36, 80.6%) were published between 2024 and 2025 and were of a low level of evidence (19/36, 52.8% level 5). Randomised and cohort data in knee OA indicate that GLP-1-RAs are associated with substantial weight loss, with accompanying improvements in pain/function and reduced progression to arthroplasty. In contrast, evidence in hip OA is sparse with weaker associations.Conclusion GLP-1-RAs represent a promising adjunct for managing individuals with OA complicated by obesity. Until further evidence emerges, GLP-1-RAs should be integrated into supervised, multimodal musculoskeletal care rather than used as standalone weight-loss agents.No data are available.

LONDON—Warfare before welfare is British Prime Minister Keir Starmer's chosen legacy as one of his final major acts of office was to deluge the U.K.'s military with cash on Tuesday.

LOCATION The Thornbury Local 635 High St, Thornbury VIC 3071 DATE Sat 11 Jul 2026 Time 8pm PRICE